Expensive anti-aging supplements are no longer needed.
Do drugs with abundant safety and evidence work for anti-aging in the world? It attracts attention and is a topic among specialists.
The other day, I met Metformin with a diabetic specialist at a famous university medical school.
I told you that I have been taking it every day before ... he was also talking about taking it soon.
It is better to take Metformin, which has a known mechanism of action and risks, rather than an anti-aging supplement with no known risk and high cost and no evidence.
Metformin has been used for the treatment of diabetes since the 1950 era and has been used for more than 60 years. In the United States, the US Food and Drug Administration (FDA) approved in the 1990 era and is now the first choice for diabetes treatment.
Metformin is also widely used as a diabetes treatment in Japan. The price of 1 tablets 250mg is less than 10 yen and is inexpensive. Because it is effective and cheap, it has the advantage of reducing the economic burden of diabetics.
“There are already many reports on the therapeutic effects of metformin, and it is also known to reduce the onset of diabetes in the pre-diabetes group,” says Professor Neil Balgirai (Endocrinology) of Albert Einstein Medical University in the United States.
The research team of Prof. Balgirai et al. Will start this year's “Aging Suppression by Metformin” (TAME) study at 15 medical institutions in the United States. 70 ~ 80 aged 3,000 elderly patients will be divided into groups taking metformin and those not taking it, followed by 5 ~ 7 follow-up survey. It is said to examine the difference in life span, heart disease such as myocardial infarction, cancer, dementia, etc.
“We expect Metformin to have an anti-aging effect that extends the healthy lifespan that indicates how long you can be healthy and healthy. It seems that not only diabetics but also healthy people may have anti-aging effects. “Professor Balgirai says.
A large UK study, UKPDS, confirmed that metformin reduces arteriosclerosis and reduces the risk of developing cardiovascular disease in patients with 2 diabetes compared to other treatments.
A study by the National Institute of Aging has shown that mice treated with metformin have an increased lifespan of 5% compared to mice not. Metformin-administered mice had fewer calories, lower cholesterol levels, and fewer kidney diseases and cancer.
In addition, a research team of professors Balgirai et al., Who have about 7 million 8,000 diabetics and about 7 million 8,000 non-diabetics, will live long for diabetics treated with metformin. It was shown that. 70 diabetics who received metformin had a 15% reduction in mortality compared to non-diabetics.
Many studies have reported that metformin has cancer prevention effects. It is known that diabetic patients have a high risk of developing cancer. Insulin and insulin-like growth factors promote some cancers, and patients with type X diabetes often have high levels of insulin in the blood for years before they are diagnosed.
Metformin does not increase the amount of insulin produced, and may suppress cancer growth. In addition, it has an action of activating a tumor suppressor gene and is considered to have an antioxidant action to prevent an increase in active oxygen that damages blood vessels.
Metformin is unique in that it does not promote insulin secretion but has a wide range of extrapancreatic effects. Metformin has a hypoglycemic action by inhibiting gluconeogenesis, promoting the utilization of sugar in the periphery such as muscles, and inhibiting glucose absorption from the intestinal tract.
The mechanism of action of metformin has recently been elucidated and has been shown to activate an enzyme called AMP kinase. This enzyme promotes gluconeogenesis that synthesizes glucose in the liver, and has the effect of increasing ATP, which produces energy necessary for life activity, related to the pathway of synthesizing neutral fat and cholesterol. When liver AMP kinase is activated, fat is encouraged to burn as an energy source.
Metformin has a long history of treatment, but lactic acidosis caused by phenformin, a biguanide, was reported in the 1970 era. Lactic acidosis is a condition in which lactic acid accumulates in the blood due to various causes, and the blood is extremely acidic.
Metformin increases lactic acid, but it is normally balanced because lactic acid is metabolized in the liver. However, lactic acid metabolism, liver damage, renal dysfunction, etc. will cause the balance of lactic acid levels to be lost and increase the risk of lactic acidosis. In Japan, it is said that metformin should be carefully administered to elderly people.
However, in the 1990 era, biguanide drugs were reviewed globally, and large-scale clinical trials using metformin were conducted in Europe and the United States. The incidence of lactic acidosis in metformin users was found to be low.
Metformin has many merits, such as no increase in body weight and the effect of improving insulin resistance, compared with the SU agent which is an oral diabetes drug widely used so far. Many researchers conclude that it is one of the best options because it is used cheaply and is inexpensive because it is also available in generic drugs.
Dr. Nir Barzilai on the TAME Study (Alliance for Aging Research 2015 year 4 month 28 day)
Study shows type 2 diabetics can live longer than people without the disease (University of Cardiff 2014 year 8 month 8 day)